A patent review on HMGB1 inhibitors for the treatment of liver diseases

Richa Raj,Pingping Shen,Boyang Yu,Jian Zhang
DOI: https://doi.org/10.1080/13543776.2024.2338105
2024-04-11
Expert Opinion on Therapeutic Patents
Abstract:Introduction HMGB1 is a non-histone chromatin protein released or secreted in response to tissue damage or infection. Extracellular HMGB1, as a crucial immunomodulatory factor, binds with several different receptors to innate inflammatory responses that aggravate acute and chronic liver diseases. The increased levels of HMGB1 have been reported in various liver diseases, highlighting that it represents a potential biomarker and druggable target for therapeutic development.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?